医学
神经母细胞瘤
不利影响
肿瘤科
干细胞
重症监护医学
自体干细胞移植
免疫疗法
内科学
总体生存率
癌症
遗传学
生物
细胞培养
作者
Nick Bird,Nicole Scobie,Antonia Palmer,Donna Ludwinski
摘要
High-dose chemotherapy with autologous stem cell transplant (ASCT) has been a mainstay of high-risk neuroblastoma treatment for several decades, demonstrating improvements in event-free survival but with risks of serious or even life-threatening acute toxicities, severe long-term adverse health effects for survivors, and ongoing contention regarding overall survival benefit. The merits of ASCT in the modern era of immunotherapy are a source of debate among parents, advocates, and some physicians. Here we examine evidence for and against ASCT, explore parent attitudes and their turmoil over decision-making, and strongly encourage international research consortia to develop a coordinated strategy to accelerate progress toward a future that avoids the routine use of ASCT in high-risk neuroblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI